VentriPoint to Exhibit at EUROECHO 2012 in Athens
December 04 2012 - 7:00AM
Marketwired
VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF) will be
exhibiting at the Annual Meeting of EUROECHO & other Imaging
Modalities 2012 from December 5th to 8th in Athens, Greece.
VentriPoint is focused on imaging the right heart using low-cost
ultrasound to make right-heart diagnostics faster and more cost
effective. Starting with 2D ultrasound images, the VentriPoint
software uses Knowledge Based Reconstruction (KBR) to calculate
accurate right-ventricle volumes and function. Clinical studies
have shown that the information from VentriPoint's technique is
equivalent to Magnetic Resonance Imaging (MRI), the current
standard of care. VentriPoint's booth number is D4.
The VentriPoint technique will be presented at EUROECHO in
scientific sessions focused on the analysis of the right ventricle
by its many operators, who are leading cardiologists. The strategy
of installing at leading institutions is now starting to pay
dividends as more and more users incorporate case studies in their
presentations. For example; Dr. John Simpson, from Evelina
Children's Hospital in London, UK, will be speaking about "Is 2D
echo obsolete?" and updating his colleagues about his experience
using the VentriPoint VMS(TM) heart analysis system.
"This is VentriPoint's second year attending EUROECHO", said
Amol Karnick, VP of Sales and Business Development, "We expect a
busy four days as we reconnect with people from last year to show
them our progress in developing applications such as pulmonary
hypertensions and new hardware changes to make the VMS(TM) more
user friendly. Our presence in Europe is growing stronger and we
have great relationships with leading institutions to continue our
forward momentum".
VentriPoint has 10 installed VMS(TM) heart analysis systems
throughout Europe including England, Germany, France, Netherlands,
Switzerland, Austria and Norway and has 2 more systems expected to
be installed in Europe in 2012. The company is announcing the
launch of its German and French versions and it will be adding more
languages as it continues to expand within Europe. We have an
excellent pipeline of potential customers who are indicating to us
their desire to acquire the VMS(TM) as soon as possible in
2013.
The VMS(TM) is approved for clinical use in Canada and Europe
and is for investigational use only in the United States.
About EUROECHO
EUROECHO 2012 is one of the largest echo and imaging meetings in
the world and is expected to attract more than 3,000 cardiologists,
internists, cardiac surgeons and sonographers from over 90
countries. This year promises four days of the latest science and
treatment monitoring options in cardiovascular imaging. Nearly 700
original scientific abstracts will be presented by international
scientists on hot topics such as increasing the viability of hearts
for transplantation, cardiovascular risks in patients with HIV, the
links between obstructive sleep apnea and heart disease, and
assessing the cardiac damage induced by cancer drugs.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor
patients with heart disease, a leading cause of death in developed
countries. VMS(TM) is the first cost-effective and accurate
diagnostic tool for measuring right ventricle heart function.
Congenital heart disease in children and adults and pulmonary
arterial Hypertension are the first applications in a suite of
applications for all major heart diseases including cardiovascular
disease and heart failure - a multi-billion dollar market
potential. Canada and Europe (CE Mark) have granted approval for
the sale of its VMS(TM) diagnostic tool and the company is pursuing
the US-FDA marketing clearance through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press
release that are not historical facts contain forward-looking
information that involves risk and uncertainties. All statements,
other than statements of historical facts, which address
VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of
business judgment as well as assumptions made by and information
currently available to management. When used in this document, the
words "may", "will", "anticipate", "believe", "estimate", "expect",
"intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on
these forward-looking statements. These statements reflect a
current view of future events and are subject to certain risks and
uncertainties as contained in the Corporation's filings with
Canadian securities regulatory authorities. Should one or more of
these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially
from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to
update, revise or otherwise publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof, or to reflect the occurrence of any unanticipated
events. Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
Contacts: VentriPoint Diagnostics Ltd. Dr. George Adams CEO
(206) 283-0221, ext. 401gadams@ventripoint.com